Results 81 to 90 of about 3,441 (189)
HIV Medicine, Volume 26, Issue 8, Page 1184-1198, August 2025.Abstract Objective This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Ishfaq Rashid +12 more
wiley +1 more source
Enfuvirtide administration in HIV-positive transgender patient with soft tissue augmentation : US evaluation [PDF]
, 2010 Enfuvirtide is a large protein that should be injected subcutaneously to ensure an appropriate absorption. Here we report the case of a transgender HIV-positive patient receiving enfuvirtide with an individualized background regimen of antiretroviral ...
L. Ferraris +6 more
core
Journal of the International AIDS Society, Volume 28, Issue 7, July 2025.Abstract Introduction Despite its reversal in July 2019, the World Health Organization warning issued in May 2018 of potential teratogenicity associated with dolutegravir (DTG) may have produced persistent sex disparities in access to DTG. We compared DTG uptake of people with HIV (PWH) by sex in Latin America and the Caribbean (LAC) and its potential ...
Fernanda F. Fonseca +15 more
wiley +1 more source
Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV
Drugs in Context, 2018 A review of literature published regarding non-tenofovir antiretroviral agents causing renal adverse effects was conducted. The literature involving renal adverse effects and antiretroviral therapy is most robust with protease inhibitors, specifically ...
Milena M McLaughlin +2 more
doaj +1 more source
Latest Progress on Tuberculosis and HIV Co‐Infection: A Closer Look at People of Different Ages
Advanced Therapeutics, Volume 8, Issue 4, April 2025.Tackling the problem of tuberculosis (TB) and human immunodeficiency virus (HIV) co‐infection is a serious global health concern affecting people of all ages. This review presents the characteristics of both diseases, current treatment and diagnostic guidelines, associated problems, innovations in disease management, and overall effects on global ...
Anna Yusuf Aliyu, Oluwatoyin A. Adeleke
wiley +1 more source
Pharmacokinetics‐Based Design of Subcutaneous Controlled Release Systems for Biologics
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 4, Page 668-680, April 2025.ABSTRACT Protein therapeutics have emerged as an exceedingly promising treatment modality in recent times but are predominantly given as intravenous administration. Transitioning to subcutaneous (SC) administration of these therapies could significantly enhance patient convenience by enabling at‐home administration, thereby potentially reducing the ...
Abigail K. Grosskopf +3 more
wiley +1 more source
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide [PDF]
, 2017 Objectives We studied gp41 mutations associated with failing enfuvirtide salvage therapy. Methods This multicentre study involved patients with HIV-1 plasma viral load (pVL) > 5000 copies/mL after at least 3 months of uninterrupted enfuvirtide therapy ...
Brun-Vézinet, Françoise +21 more
core
Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide [PDF]
, 2010 We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases.
Dominique Rousset +9 more
core +1 more source
No Evidence for Decay of the Latent Reservoir in HIV‐1–Infected Patients Receiving Intensive Enfuvirtide‐Containing Antiretroviral Therapy [PDF]
, 2010 Human immunodeficiency virus type 1 (HIV-1) persists in a latent reservoir of infected resting memory CD4 cells in patients receiving antiretroviral therapy.
Siliciano, Robert F. +11 more
core +2 more sources
A Review of Electroanalytical Techniques for Determination of Anti-HIV Drugs
International Journal of Electrochemistry, 2011 Until now after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of ...
Burçin Bozal +2 more
doaj +1 more source